NCT00357591

Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation

MOMENTUM: Multicenter Trial of the Orqis Medical CRS for the Enhanced Treatment of CHF Unresponsive to Medical Therapy

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Orqis Medical Corporation · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The Company's proprietary products are based on Orqis Medical's hypothesis, supported by early clinical data, that increasing and maintaining continuous blood flow in the descending aorta, known as continuous aortic flow augmentation or CAFA, improves hemodynamics in heart failure patients. The clinical impact of the hemodynamic improvement is currently being evaluated to determine the effects of CAFA on stopping or reversing the progression of heart failure through three physiological effects: * VASCULAR - Reducing systemic vascular resistance * RENAL - Improving renal function * CARDIAC - Reducing cardiac workload

Conditions

• Heart Failure, Congestive

Interventions

Type	Name	Description
DEVICE	Continuous Aortic Flow Augmentation	1.0-1.5 lpm augmented blood flow

Timeline

• Start date: 2004-09-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2006-07-27
• Last updated: 2009-12-25

Locations

1 site across 1 country: United States